Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.
2016 ◽
Vol 34
(15_suppl)
◽
pp. 9005-9005
◽
Keyword(s):
Keyword(s):
Keyword(s):
2009 ◽
Vol 71
(2)
◽
pp. 117-126
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):